Company intelligence / Profile preview

Biotheus

Ownership: Private
Development stage: Phase 2

Overview

Biotheus has multiple programs in clinical development, including PM8001 which was approved by the USFDA to enter Phase II studies in 2021. The company has established strategic partnerships with BioNTech and Hansoh Pharma for developing various antibody candidates.

Therapeutic areas: OncologyImmunology
Modalities: Antibodies (monoclonal antibodies, bispecific antibodies, antibody-drug conjugates)biologicsVHH binders
Industry: Biotech

Drug pipeline

3 assets

BNT327/PM8002

Phase 2

Indications: Solid tumors

2 more assets in the full pipeline.

Request access →

Partnerships

BioNTechHansoh Pharma

Beyond the preview

Go deeper on Biotheus.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biotheus.

Explore the full profile